These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35002037)

  • 21. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
    Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
    Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
    Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report.
    Jewett BE; Miller MN; Ligon LA; Carter Z; Mohammad I; Ordway GA
    BMC Psychiatry; 2020 Apr; 20(1):171. PubMed ID: 32295563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
    Shin W; Noh JJ; Baek SH; Kim BG; Lim MC; Park SY
    Anticancer Res; 2021 Sep; 41(9):4603-4607. PubMed ID: 34475088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    Okamoto A; Kondo E; Nakamura T; Yanagida S; Hamanishi J; Harano K; Hasegawa K; Hirasawa T; Hori K; Komiyama S; Matsuura M; Nakai H; Nakamura H; Sakata J; Tabata T; Takehara K; Takekuma M; Yokoyama Y; Kase Y; Sumino S; Soeda J; Suri A; Aoki D; Sugiyama T
    J Gynecol Oncol; 2021 Mar; 32(2):e16. PubMed ID: 33327047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niraparib - A promising drug with hematological toxicity.
    Patibandla NS; Monga DK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

  • 33. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
    van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Smith JA; Le T; Martin GA; Gaikwad A; Sun CH; Nugent EK; Lucci JA
    Gynecol Oncol; 2019 Feb; 152(2):265-269. PubMed ID: 30466807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
    J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.